Monday, July 09, 2012 7:59:59 AM
I haven't read or seen this alert. I don't believe it was released on yahoo. I don't know what kind of promotion this was as it didn't seem to be widely distributed to the public. For me, all that matters are the results. So far, preclinical data is very impressive. Of course, it's just preclinical data. The company needs to file the IND and begin human testing. If results are confirmed, the stock will do very well and the company could seriously look to big pharma for a partnership or even a buyout. I bought in around .20 because the risk/reward looked very intriguing. The float is small and i love that they are working to find a treatment for breast cancer. Although money is currently tight, they have collaborations with university hospitals and are receiving grants so they are able to keep the lights on for now. These small bio plays are always a crap shoot but if they hit, you could make a lot of money. PCYC was a penny stock a few years ago. THLD was around $1 back in February. You never know. Let's get this IND filed first and see what happens.
"Don't worry about the world coming to an end today. It's already tomorrow in Australia"
Recent SBFM News
- Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year • ACCESS Newswire • 04/06/2026 12:30:00 PM
- Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea • ACCESS Newswire • 10/28/2025 11:45:00 AM
- Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline • ACCESS Newswire • 10/20/2025 11:45:00 AM
- Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin • ACCESS Newswire • 10/16/2025 11:45:00 AM
- Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience • ACCESS Newswire • 10/14/2025 11:00:00 AM
- Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections • ACCESS Newswire • 10/09/2025 12:00:00 PM
